NASDAQ$PODD

Insulet Corp. · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Insulet reported a revenue increase of 16% year-over-year.

Insulet Corporation reported second quarter 2021 revenue of $263.2 million, up 16.3% compared to the prior year. Total Omnipod revenue increased by 19.9%, driven by growth in both U.S. and International markets. The company is reaffirming its revenue guidance range of 16% to 20% for the year ending December 31, 2021.

  • Second quarter 2021 revenue increased by 16.3% to $263.2 million.
  • Total Omnipod revenue grew by 19.9% to $242.1 million.
  • Gross margin increased to 69.4%, up 640 basis points.
  • Adjusted EBITDA reached $52.3 million, representing 19.9% of revenue.

Headline financials

Total Revenue

$263M

Previous: $226M+16.3%
EPS (adj)

$0.23

Previous: $0.22+4.5%
Gross Margin

69.4%

Previous: 63.0%+10.2%
Adjusted EBITDA

$52.3M

Previous: $44.2M+18.3%
Capital Expenditures

-$52.8M

Previous: -$51.7M-2.1%
Free Cash Flow

-$77.8M

Previous: -$37.3M-108.6%
Net Income

-$25M

Previous: $14.4M-273.6%
Operating Income

$26.3M

Previous: $27.5M-4.4%
Gross Profit

$183M

Previous: $143M+28.2%
Cash & Equivalents

$855M

Previous: $779M+9.7%
Total Assets

$1.92B

Previous: $1.63B+18.3%
Stock-Based Comp

$9M

Previous: $5.8M+55.2%

Revenue & EPS history

Insulet · Revenue · Quarterly

$263M

Q2 2021+16.3%vs Q2 2020
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Revenue by segment

Insulet · $263M total across 3 segments · Q2 2021

  • U.S. Omnipod
    $151M+16.8%
  • International Omnipod
    $91.6M+25.1%
  • Drug Delivery
    $21.1M-13.2%

Forward guidance

The Company expects revenue growth of 11% to 18% for the quarter ending September 30, 2021.

Tailwinds

  • Total Omnipod revenue growth of 17% to 23%
  • U.S. Omnipod revenue growth of 23% to 28%
  • International Omnipod revenue growth of 8% to 14%

Headwinds

  • Drug Delivery revenue decline of (40)% to (28)%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+3.0%

Avg return

Earnings day

+4.0%

Avg return

5 days after

+5.2%

Avg return

30 days after

65%

41 / 63 earnings

Positive

+20.7%

Q1 2025

Best reaction

-16.8%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.1%+3.8%+1.4%
Q4 2025+3.5%+1.2%-7.8%
Q3 2025+2.8%+3.8%-3.2%
Q1 2025+20.7%+25.1%+21.3%
Q4 2024-1.9%-6.1%-6.9%
Q3 2024+12.0%+15.0%+10.9%
Q2 2024-4.3%+2.2%+12.8%
Q1 2024-5.5%-1.9%+9.0%
Q4 2023-4.3%-13.4%-14.6%
Q3 2023+18.1%+17.5%+39.6%
Q2 2023-11.9%-13.6%-31.6%
Q1 2023+2.4%-0.4%-12.4%
Q4 2022+2.3%-4.0%+7.8%
Q3 2022+19.6%+16.3%+17.7%
Q2 2022+2.4%-0.8%-2.5%
Q1 2022-16.8%-23.0%-13.9%
Q4 2021+8.9%+12.9%+7.4%
Q3 2021-1.3%+2.0%-15.6%
Q2 2021-1.3%+0.1%+8.4%
Q1 2021-11.4%-13.0%+2.8%
Q4 2020+2.3%+1.0%+1.0%
Q3 2020+14.6%+14.4%+16.0%
Q2 2020+1.1%-7.7%-4.9%
Q1 2020+5.4%+6.8%-13.3%
Q4 2019-13.2%-8.4%-14.2%
Q3 2019+9.9%+16.4%+26.5%
Q2 2019+18.4%+26.0%+30.0%
Q1 2019+14.0%+20.9%+29.4%
Q4 2018+5.1%+7.7%+6.6%
Q3 2018+0.4%-2.4%-4.9%
Q2 2018+2.4%+2.6%+24.3%
Q1 2018-3.6%-4.3%+9.0%
Q4 2017+3.6%-1.1%+8.6%
Q3 2017+18.9%+22.7%+21.0%
Q2 2017+6.5%+8.6%+15.5%
Q1 2017-5.8%-4.6%+0.9%
Q4 2016-5.2%+0.7%-7.2%
Q3 2016+9.9%+10.3%+3.9%
Q2 2016+18.5%+23.3%+22.2%
Q1 2016-4.0%
Q4 2015+9.0%
Q3 2015+13.2%
Q2 2015+10.0%
Q1 2015-11.0%
Q4 2014-4.5%
Q3 2014+5.1%
Q2 2014-2.2%
Q1 2014-14.0%
Q3 2013-3.4%
Q2 2013+10.2%
Q1 2013+12.0%
Q4 2012+9.3%
Q3 2012+4.2%
Q2 2012+4.8%
Q1 2012+2.1%
Q4 2011-3.5%
Q3 2011+0.5%
Q2 2011+2.9%
Q1 2011+0.6%
Q4 2010-2.0%
Q3 2010+2.5%
Q2 2010+0.3%
Q1 2010+11.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro